Collaboration Reflects a Shared Commitment to “Doing Things Differently”
Parsippany, NJ — July 16, 2025 — YARAL Pharma Inc., the U.S. generics subsidiary of IBSA (Institut Biochimique SA), a global pharmaceutical company headquartered in Lugano, Switzerland, today announced its sponsorship of race car driver Charles Hoopes through the Back Seat Drivers racing series. As part of the sponsorship, the YARAL Pharma logo will appear on Hoopes’ race car and uniform throughout the 2025 racing season, starting with his appearance at Geezers at the Grove at Maple Grove Raceway in Mohnton, PA on July 19, 2025.
“Charles’s grit and determination align perfectly with our values at YARAL,” said Stephen Beckman, CEO of YARAL Pharma. “We believe in doing things differently—whether it’s how we approach business, support our partners, or serve our patients. Charles embodies this mindset through his unconventional journey into racing. We’re proud to support him and the Back Seat Drivers series as a reflection of our shared philosophy.”
Unlike many in the sport, Hoopes came to racing later in life, transforming a personal passion into a career—an inspiring example of bold, purpose-driven action.
“My route into racing wasn’t typical—which is why this partnership with YARAL Pharma really resonates,” said Charles Hoopes. “Racing demands both physical and mental strength. The heat, the muscle strain, the intensity all adds up. Partnering with a company committed to innovative approaches to care and recovery makes a real difference.”
This sponsorship highlights YARAL Pharma’s continued investment in partnerships that reflects its mission of challenging convention and improving lives through accessible, high-quality generic medicines. To learn more about Charles Hoopes and YARAL Pharma’s commitment to “Doing Things Differently,” visit www.yaralpharma.com.
About YARAL Pharma
YARAL Pharma Inc. (Parsippany, NJ) is the U.S. generics subsidiary of IBSA, a global pharmaceutical company headquartered in Switzerland. Committed to advancing healthcare through high-quality authorized generics (AGs) and complex generic medicines, YARAL Pharma delivers exceptional value with a focus on patient outcomes, reliable supply, and personalized customer service. The company brings a bold, human-centered approach to the U.S. market—dedicated to doing things differently. Learn more at www.yaralpharma.com, or contact info@yaralpharma.com or 866-218-9009.
About IBSA
IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical company with 20 subsidiaries in Europe, China and the United States. Its products are distributed in over 90 countries and its research and development activity focuses on 10 therapeutic areas. In 2025, IBSA celebrates the 40th anniversary of its acquisition by current President and CEO Arturo Licenziati, who transformed the company into a multinational that employs over 2,300 people worldwide. IBSA’s growth and development can be attributed to the ability to innovate by perfecting already known molecules, as well as to the desire to look to the future in a responsible and transparent way, thanks to the dedication and dynamism of its people.
Media Contact:
Daina Basile
Kovak-Likly Communications
dbasile@klcpr.com
YPM-1157-v1